PEPG
PepGen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PEPG
Pepgen Inc.
A clinical-stage biotechnology company that developing treatment for severe neuromuscular and neurological diseases
321 Harrison Avenue, Boston, MA 02118
--
PepGen Inc., was incorporated in Delaware, USA on January 25, 2018. The company is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of serious neuromuscular and neurological diseases. They build on more than ten years of research and development to enhance oligonucleotides or build EDO platforms and use cell-penetrating peptides to improve the absorption and activity of conjugated oligonucleotide therapies. The technology was originally developed by researchers at the University of Oxford in collaboration with the UK Research Council for Research and Innovative Medicine. They are using these EDO peptides to produce a range of oligonucleotide therapeutic candidates.
Company Financials
EPS
PEPG has released its 2025 Q3 earnings. EPS was reported at -0.52, versus the expected -0.56, beating expectations. The chart below visualizes how PEPG has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
